Utility of three endoscopic IBD activity scores highlighted in two studies
FROM GASTROENTEROLOGY
The results included a satisfactory level of intrainvestigator and interinvestigator reliability, indicating that the UCEIS is simple to use and also "reliably evaluates the overall endoscopic severity of UC and accounts for 88% of the variance between endoscopists," the authors concluded.
The study was the first step in the validation of the UCEIS and has "confirmed the reliability of the UCEIS, even if further validation is needed to establish thresholds for remission, the clinical relevance of different UCEIS scores, and responsiveness of the UCEIS to change in disease status," they noted.
The CD study was partly funded by Janssen Biotech; Dr. Ferrante was supported by the Belgian Society of Gastrointestinal Endoscopy and by Funds for Scientific Research, Belgium. The authors disclosed serving on advisory committees and review panels of, or serving as consultants and speakers for, multiple pharmaceutical manufacturers, as well as receiving grants or research support from the companies, including Janssen and Abbott. Several authors were employees of Janssen Biotech and Janssen Biologics, the manufacturer of infliximab. One author had no disclosures.
The UCEIS study was funded by Warner Chilcott, and one author was an employee of the company. The authors disclosed serving as consultants, advisers, and/or speakers for, and receiving research grants from, multiple pharmaceutical companies. Several authors had no disclosures.
